12 Best Genomics Stocks to Invest In

Page 4 of 11

8. CRISPR Therapeutics AG (NASDAQ:CRSP)

Number of Hedge Fund Holders: 21  

Analysts’ Upside Potential as of December 24: 20.98%

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the Best Genomics Stocks.

TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while reducing its price target from $82 to $74. The firm stated that the modification came after revisions to its business model following the third-quarter report.

Besides that, it was reported on December 22, 2025, that CRISPR Therapeutics AG (NASDAQ:CRSP) offered clinical updates on zugocaptagene geleucel. It is also known as zugo-cel (previously CTX112), an experimental allogeneic CAR T treatment that targets CD19 for hematologic malignancies and autoimmune diseases. A Phase 1 basket trial for autoimmune rheumatologic disorders is now evaluating Zugo-cel. Four patients treated with a 100 million cell dose and monitored for at least 28 days exhibited cell expansion similar to that observed at the same dose in B-cell lymphoma trials as of the December 17, 2025, data cut-off. B-cell depletion was seen to occur quickly and persistently in one to two days. On Day 28, all patients had considerable clinical improvement. A patient with systemic lupus erythematosus who was unresponsive to nine previous treatments continued to experience drug-free DORIS clinical remission through the sixth month of treatment.

As of November 20, 2025, ten patients with refractory or relapsed large B-cell lymphoma were receiving treatment at the recommended Phase 2 dose of 600 million cells for hematologic malignancies. There were reports of a 90% overall response rate and a 70% full response rate. After 12 months of follow-up, 67% of patients were in full response.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene editing firm that focuses on the development of CRISPR/Cas9-based therapies.

Page 4 of 11